Savara Inc. (NASDAQ:SVRA) Stock Has Consensus Target Price of $10.25

Shares of Savara Inc. (NASDAQ:SVRA) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.25.

Several brokerages have commented on SVRA. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Citigroup reissued a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on Savara in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Thursday. Finally, Royal Bank Of Canada set a $10.00 target price on shares of Savara in a research note on Wednesday, October 7th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SVRA. Renaissance Technologies LLC increased its holdings in Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after buying an additional 320,572 shares during the period. Walleye Capital LLC acquired a new position in shares of Savara in the 2nd quarter valued at $1,532,000. BlackRock Inc. acquired a new position in shares of Savara in the 2nd quarter valued at $76,966,000. Deutsche Bank AG bought a new position in shares of Savara during the 2nd quarter worth about $5,328,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Savara during the 2nd quarter worth about $42,977,150. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Up 4.0%

SVRA stock opened at $4.63 on Tuesday. Savara has a one year low of $3.60 and a one year high of $7.01. The firm has a 50-day moving average of $5.21 and a two-hundred day moving average of $5.39. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, research analysts expect that Savara will post -0.66 EPS for the current year.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.